EUVIMEDEUVIMED entdecken
MetaanalyseSystematische ÜbersichtOpen Access

Meta‐Analysis on the Harm of Systemic Glucocorticosteroids in Inflammatory Upper Airway Disease and Asthma: An EAACI Task Force

Sophie Scheire iD, Evelijn Lourijsen iD, Manon Blauwblomme, Maria Dib iD, Ioana Agache iD, Claus Bachert iD, Koen Boussery iD, Adam Chaker iD, Roos Colman iD, Stefano Del Giacco iD, Ibon Eguiluz-Gracia iD, Wytske Fokkens iD und 17 weitere

Allergy · 2026-09 · 81 (9) · 3071-3106

DOI: 10.1111/all.70332 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Allergy, online erschienen am 21.04.2026. Verfasst von Sophie Scheire und 28 weiteren Autor:innen. Beteiligte Einrichtung: Pharmaceutical Care Unit, Faculty of Pharmaceutical Sciences, Ghent University, Ghent, Belgium. Hauptthemen laut MEDLINE: Asthma, Glucocorticoids, Respiratory Tract Diseases. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: European Academy of Allergy and Clinical Immunology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Systemic glucocorticosteroids (sGCS) are widely used in the treatment of chronic inflammatory airway diseases such as rhinitis, rhinosinusitis and asthma. It is well‐known that systemic use is linked to multiple adverse effects (AEs) both in the short‐ and the long‐term. However, less is known about the safety of multiple short courses of sGCS. Currently there is no established agreement on the acceptable cumulative exposure to sGCS, considering the potential for various AEs. This systematic review and meta‐analysis evaluated sGCS‐related AEs in both upper and lower inflammatory airway disease, with a particular focus on short‐ and long‐term risks. We further evaluated whether a dose–response relationship existed between the daily and cumulative dosages of sGCS and the occurrence of those AEs. Our meta‐analysis confirmed that cumulative dosages between 500 mg and 1 g prednisolone‐equivalent significantly increase the risk of most AEs, with risks increasing with incremental dose. These findings underscore the importance of: (a) judicious sGCS prescription and need for steroid stewardship, due to their potential for short‐ and long‐term complications, occurring even with repeated short courses, and (b) prioritization of steroid‐sparing approaches (e.g., biologicals) to avoid reaching a cumulative dose of 500 mg.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AsthmaGlucocorticoidsRespiratory Tract DiseasesHumansRhinosinusitis

Stichwörter der Autor:innen

adverse eventsasthmachronic rhinosinusitisrhinitissystemic glucocorticosteroids

Substanzen

Glucocorticoids

Autor:innen und Institutionen

  • Pharmaceutical Care Unit, Faculty of Pharmaceutical Sciences, Ghent University, Ghent, Belgium.
  • Department of Head and Skin, Upper Airways Research Laboratory, Ghent University, Ghent, Belgium.
  • Department of Otorhinolaryngology, Amsterdam University Medical Center, Amsterdam, the Netherlands.
  • Department of Otorhinolaryngology, Head and Neck Surgery, Greifswald University Medical Center, Greifswald, Germany.
  • Transylvania University, Brasov, Romania.
  • University Hospital of Münster, Münster, Germany.

ORCID-Profile: Sophie Scheire, Evelijn Lourijsen, Maria Dib, Ioana Agache, Claus Bachert, Koen Boussery, Adam Chaker, Roos Colman, Stefano Del Giacco, Ibon Eguiluz-Gracia, Wytske Fokkens, Simon Gane, Peter Hellings, Ludger Klimek, Miguel Maldonado, Juan Maza-Solano, Ralph Mösges, Joaquim Mullol, Oliver Pfaar, Sietze Reitsma, Michael Rudenko, Mohamed H Shamji, Peter Valentin Tomazic, Sanna Toppila-Salmi, Philippe Gevaert, Valerie Hox

Förderung

  • European Academy of Allergy and Clinical Immunology

Zitieren

APA

Scheire, S., Lourijsen, E., Blauwblomme, M., Dib, M., Agache, I., Bachert, C., Boussery, K., Chaker, A., Colman, R., Del Giacco, S., Eguiluz-Gracia, I., Fokkens, W., Gane, S., Hellings, P., Hopkins, C., Klimek, L., Maldonado, M., Maza-Solano, J., Mösges, R., …, & Hox, V. (2026). Meta‐Analysis on the Harm of Systemic Glucocorticosteroids in Inflammatory Upper Airway Disease and Asthma: An EAACI Task Force. Allergy, 81(9), 3071-3106. https://doi.org/10.1111/all.70332

Vancouver

Scheire S, Lourijsen E, Blauwblomme M, Dib M, Agache I, Bachert C, et al. Meta‐Analysis on the Harm of Systemic Glucocorticosteroids in Inflammatory Upper Airway Disease and Asthma: An EAACI Task Force. Allergy. 2026;81(9):3071-3106. doi:10.1111/all.70332

BibTeX
@article{Scheire2026,
  author = {Scheire, Sophie and Lourijsen, Evelijn and Blauwblomme, Manon and Dib, Maria and Agache, Ioana and Bachert, Claus and Boussery, Koen and Chaker, Adam and Colman, Roos and Del Giacco, Stefano and Eguiluz-Gracia, Ibon and Fokkens, Wytske and Gane, Simon and Hellings, Peter and Hopkins, Claire and Klimek, Ludger and Maldonado, Miguel and Maza-Solano, Juan and Mösges, Ralph and Mullol, Joaquim and Pilette, Charles and Pfaar, Oliver and Reitsma, Sietze and Rudenko, Michael and Shamji, Mohamed H and Tomazic, Peter Valentin and Toppila-Salmi, Sanna and Gevaert, Philippe and Hox, Valerie},
  title = {Meta‐Analysis on the Harm of Systemic Glucocorticosteroids in Inflammatory Upper Airway Disease and Asthma: An EAACI Task Force},
  journal = {Allergy},
  year = {2026},
  volume = {81},
  number = {9},
  pages = {3071--3106},
  doi = {10.1111/all.70332}
}
Kostenlos starten →